Saxagliptin for type 2 diabetes

Antonio R Chacra, MDDiabetes Center, Federal University of São Paulo, BrazilAbstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in patients with type 2 diabetes (T2D). By blocking D...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Chacra
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	saxagliptin dipeptidyl peptidase-4 (DPP-4) inhibitor type 2 diabetes Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/0d1ee3178ca44542a77f397f616f61e2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0d1ee3178ca44542a77f397f616f61e2
record_format	dspace
spelling	oai:doaj.org-article:0d1ee3178ca44542a77f397f616f61e22021-12-02T08:38:42ZSaxagliptin for type 2 diabetes1178-7007https://doaj.org/article/0d1ee3178ca44542a77f397f616f61e22010-09-01T00:00:00Zhttps://www.dovepress.com/saxagliptin-for-type-2-diabetes-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Antonio R Chacra, MDDiabetes Center, Federal University of São Paulo, BrazilAbstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in patients with type 2 diabetes (T2D). By blocking DPP-4, saxagliptin increases and prolongs the effects of incretins, a group of peptide hormones released by intestinal cells after meals, which stimulate glucose-dependent insulin secretion to lower blood glucose. In controlled clinical trials, saxagliptin administered as monotherapy or in combination with metformin, glyburide, or a thiazolidinedione improved glycemic control in a clinically significant manner, reflected by significant decreases in glycated hemoglobin (monotherapy, -0.5%; add-on to metformin, thiazolidinedione, or sulfonylurea, -0.6% to 0.9%; initial combination with metformin, -2.5%), fasting plasma glucose, and postprandial glucose compared with controls. Additionally, saxagliptin improved β-cell function, reflected as increases in homeostasis model assessment (HOMA)-2β. Saxagliptin was generally well tolerated; it did not increase hypoglycemia compared with controls, and was weight neutral. A meta-analysis of Phase II and III trials showed that saxagliptin did not increase the risk of major cardiovascular events. Professional organizations have updated their guidelines for T2D to include a DPP-4 inhibitor as an early treatment option—either as initial therapy in combination with metformin, or as add-on therapy for patients whose glycemia is inadequately controlled by a single oral antidiabetic drug.Keywords: saxagliptin, dipeptidyl peptidase-4 (DPP-4) inhibitor, type 2 diabetesChacraDove Medical Pressarticlesaxagliptindipeptidyl peptidase-4 (DPP-4) inhibitortype 2 diabetesSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 325-335 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	saxagliptin dipeptidyl peptidase-4 (DPP-4) inhibitor type 2 diabetes Specialties of internal medicine RC581-951
spellingShingle	saxagliptin dipeptidyl peptidase-4 (DPP-4) inhibitor type 2 diabetes Specialties of internal medicine RC581-951 Chacra Saxagliptin for type 2 diabetes
description	Antonio R Chacra, MDDiabetes Center, Federal University of São Paulo, BrazilAbstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in patients with type 2 diabetes (T2D). By blocking DPP-4, saxagliptin increases and prolongs the effects of incretins, a group of peptide hormones released by intestinal cells after meals, which stimulate glucose-dependent insulin secretion to lower blood glucose. In controlled clinical trials, saxagliptin administered as monotherapy or in combination with metformin, glyburide, or a thiazolidinedione improved glycemic control in a clinically significant manner, reflected by significant decreases in glycated hemoglobin (monotherapy, -0.5%; add-on to metformin, thiazolidinedione, or sulfonylurea, -0.6% to 0.9%; initial combination with metformin, -2.5%), fasting plasma glucose, and postprandial glucose compared with controls. Additionally, saxagliptin improved β-cell function, reflected as increases in homeostasis model assessment (HOMA)-2β. Saxagliptin was generally well tolerated; it did not increase hypoglycemia compared with controls, and was weight neutral. A meta-analysis of Phase II and III trials showed that saxagliptin did not increase the risk of major cardiovascular events. Professional organizations have updated their guidelines for T2D to include a DPP-4 inhibitor as an early treatment option—either as initial therapy in combination with metformin, or as add-on therapy for patients whose glycemia is inadequately controlled by a single oral antidiabetic drug.Keywords: saxagliptin, dipeptidyl peptidase-4 (DPP-4) inhibitor, type 2 diabetes
format	article
author	Chacra
author_facet	Chacra
author_sort	Chacra
title	Saxagliptin for type 2 diabetes
title_short	Saxagliptin for type 2 diabetes
title_full	Saxagliptin for type 2 diabetes
title_fullStr	Saxagliptin for type 2 diabetes
title_full_unstemmed	Saxagliptin for type 2 diabetes
title_sort	saxagliptin for type 2 diabetes
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/0d1ee3178ca44542a77f397f616f61e2
work_keys_str_mv	AT chacra saxagliptinfortype2diabetes
_version_	1718398405318803456

Saxagliptin for type 2 diabetes

Ejemplares similares